9 Meters Biopharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bethany Sensenig
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8480 Honeycutt Road Raleigh NC United States of America 27615
- IPO Date
- Jul 11, 2016
- CIK
- 0001551986
- Website
- 9meters.com
- Similar Companies
- Business
- 9 Meters Biopharma, Inc. (Nasdaq: NMTRQ) develops therapies for rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The clinical-stage biopharmaceutical company, founded in 2020 through the merger of Innovate Biopharmaceuticals and RDD Pharma along with the acquisition of Naia Rare Diseases, and headquartered in Raleigh, North Carolina, focuses on North American markets with a pipeline that includes vurolenatide, a proprietary long-acting injectable glucagon-like-peptide-1 (GLP-1) agonist in Phase 3 for short bowel syndrome (SBS); larazotide acetate, a tight junction regulator in Phase 3 for celiac disease; NM-136, a humanized anti-GIP monoclonal antibody for Prader-Willi Syndrome, obesity, and related disorders; NM-102, a small molecule peptide to modulate the microbiome and prevent antigen trafficking; and NM-003, a long-acting GLP-2 receptor agonist for acute graft-versus-host disease prevention. In July 2023, after exhausting strategic alternatives and facing severe funding constraints with only approximately $150,000 in cash, the company ceased operations and filed for Chapter 7 bankruptcy liquidation in the U.S. Bankruptcy Court for the Eastern District of North Carolina, resulting in Nasdaq delisting of its shares.
Drug developer 9 Meters Biopharma files for bankruptcy protection
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate
How to Find Trending Penny Stocks in 2022
What to Know About Buying Penny Stocks on June 24th
What to Know About Buying Penny Stocks on June 23rd
Why Are 9 Meters Biopharma Shares Plunging Today?
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR)
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
Top Penny Stocks to Watch? 3 Moving in Today's Trading Session
5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors